India’s Ranbaxy, Three Other Generics Named In Buy-Off Suit By U.S. FTC
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Pharmaceuticals of India has been named among four companies Cephalon is alleged to have paid to delay marketing a generic version of the American company's Provigil (modafinil) narcolepsy drug. The suit was filed in the U.S. District Court in Washington for the Federal Trade Commission, which said Cephalon had acted to protect a drug worth $800 million in annual sales. Besides Ranbaxy, which did not comment on the suit, other drug makers accused of providing $200 million worth of inducements were Barr Pharmaceuticals, Mylan Pharmaceuticals and Teva Pharmaceutical Industries. (Click here for more - a subscription may be required )